Blood plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitive impairment

Journal of Alzheimer's Disease

Volumn 38, Issue 3, 2014, Pages 567-579

  Lundström, Susanna L ^a   Yang, Hongqian ^a   Lyutvinskiy, Yaroslav ^a   Rutishauser, Dorothea ^a,b   Herukka, Sanna Kaisa ^c   Soininen, Hilkka ^c   Zubarev, Roman A ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SCIENCE FOR LIFE LABORATORY   (Sweden)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Fc; glycoproteomics; glycosylation; immunoglobulin; inflammation

Indexed keywords

GLYCAN; GLYCOPROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G FC GLYCAN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GLYCOSYLATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; SEX DIFFERENCE; UNIVARIATE ANALYSIS;

FC; GLYCOPROTEOMICS; GLYCOSYLATION; IMMUNOGLOBULIN; INFLAMMATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COMPLEMENT SYSTEM PROTEINS; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MALE; MILD COGNITIVE IMPAIRMENT; OLIGORIBONUCLEOTIDES; POLYSACCHARIDES; PRINCIPAL COMPONENT ANALYSIS; SEX FACTORS; SIALIC ACID BINDING IG-LIKE LECTIN 2; TANDEM MASS SPECTROMETRY;

EID: 84889643667     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131088     Document Type: Article

References (54)

1. Alzheimer's Association (2012) Alzheimer's disease facts and figures. Alzheimers Dement 8, 131-168.
2. Duyckaerts C, Delatour B, Potier MC (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118, 5-36.
3. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E,Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913.
4. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8, 16-30.
5. Wilson JS, Mruthinti S, Buccafusco JJ, Schade RF, Mitchell MB, Harrell DU, Gulati NK, Miller LS (2009) Anti-RAGE and Abeta immunoglobulin levels are related to dementia level and cognitive performance. J Gerontol A Biol Sci Med Sci 64, 264-271.
6. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
7. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G,Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
8. Jefferis R (2009) Recombinant antibody therapeutics: The impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30, 356-362.
9. Nimmerjahn F, Ravetch JV (2007) Fc-receptors as regulators of immunity. Adv Immunol 96, 179-204.
10. Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8, 226-234.
11. Arnold JN, Dwek RA, Rudd PM, Sim RB (2006) Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol Lett 106, 103-110.
12. Anthony RM, Wermeling F, Ravetch JV (2012) Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 1253, 170-180.
13. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P (2003) Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325, 979-989.
14. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R (2000) The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms. Mol Immunol 37, 697-706.
15. Kibe T, Fujimoto S, Ishida C, Togari H, Wada Y, Okada S, Nakagawa H, Tsukamoto Y, Takahashi N (1996) Glycosylation and Placental Transport of Immunoglobulin G. J Clin Biochem Nutr 21, 57-63.
16. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Antiinflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673.
17. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K et al. (1985) Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316, 452-457.
18. Parekh R, Isenberg D, Rook G, Roitt I, Dwek R, Rademacher T (1989) A comparative analysis of disease-Associated changes in the galactosylation of serum IgG. J Autoimmun 2, 101-114.
19. Bond A, Alavi A, Axford JS, Bourke BE, Bruckner FE, Kerr MA, Maxwell JD, Tweed KJ, Weldon MJ, Youinou P, Hay FC (1997) A detailed lectin analysis of IgG glycosylation, demonstrating disease specific changes in terminal galactose and N-Acetylglucosamine. J Autoimmun 10, 77-85.
20. Scherer HU, van derWoude D, Ioan-Facsinay A, el Bannoudi H, Trouw LA,Wang J, Haupl T, Burmester GR, Deelder AM, Huizinga TW, Wuhrer M, Toes RE (2010) Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 62, 1620-1629.
21. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LM (2000) Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-Antichymotrypsin in patients with Alzheimer's disease: Peripheral inflammation or signals from the brain? J Neuroimmunol 103, 97-102.
22. De Luigi A, Pizzimenti S, Quadri P, Lucca U, Tettamanti M, Fragiacomo C, De Simoni MG (2002) Peripheral inflammatory response in Alzheimer's disease and multiinfarct dementia. Neurobiol Dis 11, 308-314.
23. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768-774.
24. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, StreitW, Strohmeyer R, Tooyoma I, VanMuiswinkel FL,Veerhuis R,Walker D,Webster S,Wegrzyniak B,Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
25. Yang H, Lyutvinskiy Y, Soininen H, Zubarev RA (2011) Alzheimer's disease and mild cognitive impairment are associated with elevated levels of isoaspartyl residues in blood plasma proteins. J Alzheimers Dis 27, 113-118.
26. Shakib F, Stanworth DR (1980) Human IgG subclasses in health and disease. (A review). Part I. Ric Clin Lab 10, 463-479.
27. Huck S, Fort P, Crawford DH, Lefranc MP, Lefranc G (1986) Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: Comparison with the other human C gamma genes. Nucleic Acids Res 14, 1779-1789.
28. Dard P, Lefranc MP, Osipova L, Sanchez-Mazas A (2001) DNA sequence variability of IGHG3 alleles associated to the main G3m haplotypes in human populations. Eur J Hum Genet 9, 765-772.
29. Royle L, Campbell MP, Radcliffe CM, White DM, Harvey DJ, Abrahams JL, Kim YG, Henry GW, Shadick NA, Weinblatt ME, Lee DM, Rudd PM, Dwek RA (2008) HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem 376, 1-12.
30. Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, Gornik O, Supraha-Goreta S, Wormald MR, Redzic I, Campbell H, Wright A, Hastie ND, Wilson JF, Rudan I, Wuhrer M, Rudd PM, Josic D, Lauc G (2011) High throughput isolation and glycosylation analysis of IgGvariability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 10, M111.010090.
31. Chen G, Wang Y, Qiu L, Qin X, Liu H, Wang X, Wang Y, Song G, Li F, Guo Y, Li F, Guo S, Li Z (2012) Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J Proteomics 75, 2824-2834.
32. Harazono A, Kawasaki N, Itoh S, Hashii N, Matsuishi-NakajimaY, Kawanishi T,Yamaguchi T (2008) Simultaneous glycosylation analysis of human serum glycoproteins by high-performance liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 869, 20-30.
33. Hogan JM, Pitteri SJ, Chrisman PA, McLuckey SA (2005) Complementary structural information from a tryptic Nlinked glycopeptide via electron transfer ion/ion reactions and collision-induced dissociation. J Proteome Res 4, 628-632.
34. Segu ZM,Mechref Y (2010) Characterizing protein glycosylation sites through higher-energy C-Trap dissociation. Rapid Commun Mass Spectrom 24, 1217-1225.
35. Julkunen V, Niskanen E, Koikkalainen J, Herukka SK, Pihlajamaki M, Hallikainen M, Kivipelto M, Muehlboeck S, Evans AC, Vanninen R, Hilkka S (2010) Differences in cortical thickness in healthy controls, subjects with mild cognitive impairment, and Alzheimer's disease patients: A longitudinal study. J Alzheimers Dis 21, 1141-1151.
36. Lyutvinskiy Y, Yang H, Rutishauser D, Zubarev R (2013) In silico instrumental response correction improves precision of label-free proteomics and accuracy of proteomics-based predictive models. Mol Cell Proteomics 12, 2324-2331.
37. Trygg J, Holmes E, Lundstedt T (2007) Chemometrics in metabonomics. J Proteome Res 6, 469-479.
38. Lundstrom SL, Balgoma D, Wheelock AM, Haeggstrom JZ, Dahlen SE, Wheelock CE (2011) Lipid mediator profiling in pulmonary disease. Curr Pharm Biotechnol 12, 1026-1052.
39. Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, Abner E, Dawson D, 3rd (2012) Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimers Dement 8, 196-203.
40. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP,Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, Alzheimer's Disease Neuroimaging I, Australian Imaging B, Lifestyle Research G (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 69, 1318-1325.
41. Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: A key system for immune surveillance and homeostasis. Nat Immunol 11, 785-797.
42. Dorner T, Goldenberg DM (2007) Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag 3, 953-959.
43. Poe JC, Tedder TF (2012) CD22 and Siglec-G in B cell function and tolerance. Trends Immunol 33, 413-420.
44. Seite JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S (2010) IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 116, 1698-1704.
45. Schonknecht P, Pantel J, Klinga K, Jensen M, Hartmann T, Salbach B, Schroder J (2001) Reduced cerebrospinal fluid estradiol levels are associated with increased beta-Amyloid levels in female patients with Alzheimer's disease. Neurosci Lett 307, 122-124.
46. Gillett MJ, Martins RN, Clarnette RM, Chubb SA, Bruce DG, Yeap BB (2003) Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J Alzheimers Dis 5, 267-269.
47. Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31, 175-193.
48. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE (2003) Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 23, 8532-8538.
49. Fernandez-Vizarra P, Lopez-Franco O, Mallavia B, Higuera-Matas A, Lopez-Parra V, Ortiz-Munoz G, Ambrosio E, Egido J, Almeida OF, Gomez-Guerrero C (2012) Immunoglobulin G Fc receptor deficiency prevents Alzheimer-like pathology and cognitive impairment in mice. Brain 135, 2826-2837.
50. Takata K, Hirata-Fukae C, Becker AG, Chishiro S, Gray AJ, Nishitomi K, Franz AH, Sakaguchi G, Kato A, Mattson MP, Laferla FM, Aisen PS, Kitamura Y, Matsuoka Y (2007) Deglycosylated anti-Amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur J Neurosci 26, 2458-2468.
51. Fournier T, Medjoubi NN, Porquet D (2000) Alpha-1-Acid glycoprotein. Biochim Biophys Acta 1482, 157-171.
52. Duke-Cohan JS, Gu J, McLaughlin DF, Xu Y, Freeman GJ, Schlossman SF (1998) Attractin (DPPT-L), a member of the CUBfamily of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions. Proc Natl Acad Sci U S A 95, 11336-11341.
53. Maruoka M, Suzuki J, Kawata S, Yoshida K, Hirao N, Sato S, Goff SP, Takeya T, Tani K, Shishido T (2005) Identification of B cell adaptor for PI3-kinase (BCAP) as an Abl interactor 1-regulated substrate of Abl kinases. FEBS Lett 579, 2986-2990.
54. Kolev MV, Ruseva MM, Harris CL, Morgan BP, Donev RM (2009) Implication of complement system and its regulators in Alzheimer's disease. Curr Neuropharmacol 7, 1-8.